Despite the success of highly active anti-retroviral therapy in controlling virus replication in HIV-1 positive individuals, problems such as drug resistance and side effects often compromise the effectiveness of anti-HIV- 1 drug. Therefore, new anti-HIV agents with novel mechanisms of action are needed. In an effort to identify novel anti-HIV-1 agents, we have developed potent betulinic acid (BA) derivatives that inhibit HIV-1 maturation. These compounds are structurally and mechanistically novel when compared to the drugs currently used for AIDS therapy. Their potentials for treatment of AIDS are currently being evaluated under different stages of preclinical or clinical studies. Bevirimat is at the most advanced stage of drug development among the anti- HIV-1 BA derivatives. Although bevirimat is a potent HIV-1 maturation inhibitor, results of phase II clinical trials indicate that it is less effective in a subset (30-40%) of HIV-1 positive individuals. Therefore, bevirimat analogs that can overcome this high baseline drug resistance are expected to have great potential to be developed into anti-HIV-1 drugs. The objective of this study is to synthesize bevirimat analogs that overcome the high baseline drug resistance. We have previously identified the C3 side chain as the anti-HIV-1 maturation pharmacophore of bevirimat. We hypothesize that suitable modifications of the pharmacophore will create a new class of bevirimat analogs that are effective against the drug resistant viruses. We plan to test this hypothesis and accomplish the objective of this study with the following Specific Aims: (1) to synthesize BA derivatives with optimized pharmacophores. (2) To identify new terpenoid scaffolds and auxiliary groups for the synthesis of new anti-maturation inhibitors against the drug resistant viruses. (3) To determine the drug binding site and mechanism of action of the anti-HIV-1 maturation BA derivatives. Aside from the high baseline drug resistance to bevirimat, results from clinical trials have been promising. The proposed study is expected to overcome this drug resistance and, as a result, will have a high impact on developing a class of novel anti-HIV-1 maturation inhibitors for AIDS therapy.

Public Health Relevance

The goal of the proposed study is to develop potent anti-HIV-1 agents that can overcome the drug resistance associated with the HIV-1 maturation inhibitor bevirimat. Aside from the high baseline drug resistance to bevirimat, results of clinical trials have been very successful. The proposed study is expected to overcome this drug resistance and, as a result, will have high impact on developing anti-HIV-1 maturation inhibitors for AIDS therapy.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI065310-08
Application #
8463100
Study Section
AIDS Discovery and Development of Therapeutics Study Section (ADDT)
Program Officer
Gupta, Kailash C
Project Start
2006-02-01
Project End
2015-04-30
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
8
Fiscal Year
2013
Total Cost
$362,934
Indirect Cost
$130,284
Name
Duke University
Department
Surgery
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Liu, Na; Wei, Lei; Huang, Li et al. (2016) Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant Virus. J Med Chem 59:3689-704
Dang, Zhao; Ho, Phong; Zhu, Lei et al. (2013) New betulinic acid derivatives for bevirimat-resistant human immunodeficiency virus type-1. J Med Chem 56:2029-37
Asada, Yoshihisa; Sukemori, Aya; Watanabe, Takashi et al. (2013) Isolation, structure determination, and anti-HIV evaluation of tigliane-type diterpenes and biflavonoid from Stellera chamaejasme. J Nat Prod 76:852-7
Whisnant, Adam W; Bogerd, Hal P; Flores, Omar et al. (2013) In-depth analysis of the interaction of HIV-1 with cellular microRNA biogenesis and effector mechanisms. MBio 4:e000193
Sun, Lian-Qi; Zhu, Lei; Qian, Keduo et al. (2012) Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates. J Med Chem 55:7219-29
Sun, Lian-Qi; Qin, Bingjie; Huang, Li et al. (2012) Optimization of 2,4-diarylanilines as non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem Lett 22:2376-9
Qin, Bingjie; Jiang, Xingkai; Lu, Hong et al. (2010) Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors. J Med Chem 53:4906-16
Tian, Xingtao; Qin, Bingjie; Wu, Zhiyuan et al. (2010) Design, synthesis, and evaluation of diarylpyridines and diarylanilines as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. J Med Chem 53:8287-97
Tian, Xingtao; Qin, Bingjie; Lu, Hong et al. (2009) Discovery of diarylpyridine derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem Lett 19:5482-5
Huang, Li; Chen, Chin Ho (2009) Proteasome regulators: activators and inhibitors. Curr Med Chem 16:931-9

Showing the most recent 10 out of 17 publications